GERD

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Maggio 9, 2024
Vonoprazan/amoxicillin, Table, FDA, DTC, Pharmacy, Gastrointestinal disease, NERD, NDA, Hercules, Amazon Prime Video, Food, Research, Webcast, Business, Forecasting, Prescription, Cigna, PPI, PDUFA, Tablet, Patient, Physician, Ratio, Enzyme inhibitor, DDW, Marketing, Vonoprazan/amoxicillin/clarithromycin, Heartburn, Hulu, GERD, Clinical trial, GAAP, Growth, Overalls, Eosinophilic esophagitis, Pharmaceutical industry

ET

Key Points: 
  • ET
    FLORHAM PARK, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024, and provided recent business highlights.
  • A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below.
  • Phathom will host a conference call and webcast to discuss its first quarter financial results and business highlights today, May 9, 2024, at 8:30 a.m.
  • Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom's results of operations.

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

Retrieved on: 
Giovedì, Maggio 2, 2024
Johns Hopkins University, University, Mayo Clinic, Cancer, SOS, American College, Case Western Reserve University, AUC, ACG, Esophageal cancer, Prevalence, Methylation, Risk, Barrett's esophagus, Cleveland Clinic, American Journal, Lucid, Adenocarcinoma, National Cancer Institute, NPV, NGS, University of North Carolina, Gold, Detection, EGD, Patient, Research report, NCI, PPV, Medicare, Manuscript, GERD, Guideline, Gastroesophageal reflux disease, Medical imaging

NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored, prospective, multicenter clinical validation study assessing the performance of Lucid's EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Esophageal Cell Collection Device. This case-control study, led by Case Western Reserve University's Amitabh Chak, M.D., was funded through the NCI's Barrett's Esophagus Translational Research Network (BETRNet), and included renowned investigators from leading academic medical centers, including Case Western Reserve University, Mayo Clinic, Johns Hopkins University, Washington University in St. Louis, University of North Carolina, and Cleveland Clinic. EsoGuard demonstrated unprecedented early precancer detection compared to the gold standard of upper endoscopy (EGD). The manuscript, entitled Multicenter, Prospective Trial of Non-Endoscopic Biomarker-Driven Detection of Barrett's Esophagus And Esophageal Adenocarcinoma, was published in the American Journal of Gastroenterology, the leading clinical journal covering gastroenterology published on behalf of the American College of Gastroenterology (ACG).

Key Points: 
  • EsoGuard demonstrated unprecedented early precancer detection compared to the gold standard of upper endoscopy (EGD).
  • Dr. Aklog concluded, "The publication of the BETRNet study is the culmination of a period of rapid expansion of EsoGuard's clinical evidence base.
  • It represents the second peer-reviewed, and third overall, clinical validation study demonstrating consistently excellent EsoGuard performance.
  • Soon to be released data from a fourth such clinical validation study tells the same story.

Implantica's RefluxStop™ is now available in seven hospitals in Spain adding two new centers of excellence

Retrieved on: 
Giovedì, Maggio 2, 2024
Certification, PMID, Cancer, Esophagitis, Surgeon, Dysphagia, Patient, Prevalence, Barrett's esophagus, GERD

), a medtech company at the forefront of bringing advanced technology into the body, announces that Dra.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, announces that Dra.
  • More patients in Spain will have access to the innovative RefluxStop™ procedure now, given that a total of seven anti-reflux centers of excellence in the country regularly perform the procedure.
  • "It's a new day we've long awaited in the world of surgical GERD treatment," says Dra.
  • She continues, "I'm pleased to see that RefluxStop does not encircle the food passageway and restores the body's natural physiology.

Implantica Announces Real-World Clinical Data from over 200 Patients treated across five RefluxStop™ Centers in Europe Presented at SAGES in Cleveland

Retrieved on: 
Martedì, Aprile 30, 2024
FDA, Society, Certification, Gastroesophageal reflux disease, Hospital, PMID, Surgeon, Research, Dexlansoprazole, Data, Patient, GERD, Quality of life, Growth, CE, Medical device

This highly esteemed conference is the biggest meeting in the world dedicated specifically to gastrointestinal and endoscopic surgery.

Key Points: 
  • This highly esteemed conference is the biggest meeting in the world dedicated specifically to gastrointestinal and endoscopic surgery.
  • Some 2,500 SAGES members, representing the world-leading experts in gastrointestinal and endoscopic surgery, attended the SAGES Annual Meeting in Cleveland, Ohio on April 17-20.
  • It's a credit to the ongoing enthusiasm for RefluxStop™ to see the latest clinical data from five world-renowned European centers of excellence in the treatment of acid reflux diseases, presented at SAGES.
  • Dr. Forsell goes on to say, "There has been an immense interest and support in RefluxStop™ therapy from the US surgeons and scientific experts.

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

Retrieved on: 
Lunedì, Aprile 29, 2024
Education, Risk, Esophageal cancer, ECAN, Lucid, Research, Human, Heartburn, GERD

NEW YORK, April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month.

Key Points: 
  • NEW YORK, April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month.
  • ECAN, a leading patient advocacy organization focused on increasing esophageal cancer education, advocacy, awareness, and research, was founded 15 years ago by Mindy Mintz Mordecai following the tragic death of her husband of esophageal cancer.
  • Lucid and ECAN are partnering to spread the potentially life-saving message that heartburn (also known as acid reflux or GERD) can lead to highly lethal esophageal cancer and that esophageal cancer is preventable through early precancer detection.
  • "This is our 15th Esophageal Cancer Awareness Month, and we are thrilled to see so many companies and individuals paying attention and advocating for early, proactive screening.

ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024

Retrieved on: 
Mercoledì, Aprile 10, 2024
Mayo Clinic, Cancer, Genomics, Hospital, Esophageal cancer, Proteomics, Insurance, Partnership, Doctor of Philosophy, Documentation, Clinical professor, Patient, CPT, Prophase, Endoscopy, EAC, Health, GERD, Risk assessment, Medical imaging

Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection.

Key Points: 
  • Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection.
  • Early detection offers patients the opportunity for more favorable outcomes and a brighter, healthier future.
  • ProPhase intends to pursue and seeks to capture a significant share of a multi-billion-dollar market for EAC diagnostics.
  • Obtaining CPT codes is important for billing purposes, enabling ProPhase Labs to bill for providing the test services and receive reimbursement from insurance companies.

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

Retrieved on: 
Mercoledì, Aprile 10, 2024
Oncology, Health, Genetics, Other Health, Other Science, Science, Biotechnology, Steps, Education, Risk, Esophageal cancer, ECAN, CPI, Research, Hepatology, GI, Disease, Patient, Physician, Northwestern University, Diagnosis, GERD, Castle, FACP, Division, Gastroesophageal reflux disease, FACG, Pharmaceutical industry

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout the month of April.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout the month of April.
  • The Company is proud to continue its ongoing collaboration with the Esophageal Cancer Action Network (ECAN), Gastro Broadcast podcast and EndoscopyNow to help advance esophageal cancer research, prevention, education and advocacy.
  • “Unfortunately, esophageal cancer is often detected at its late stages and the five-year survival rate of esophageal cancer patients is less than 20%,”1 said Emmanuel Gorospe, M.D., MPH, CPI, FACP, FACG, FASGE, GI Medical Director at Castle Biosciences.
  • TissueCypher® is Castle’s prognostic risk-stratification test designed to predict progression to high-grade dysplasia or esophageal cancer.

Alucio™ Introduces Next Iteration of Product Advisory Board

Retrieved on: 
Giovedì, Aprile 25, 2024
Health, HCP, Medical science liaison, Gastrointestinal bleeding, PAB, Health care, MD, Market access, Cancer, Biology, MBA, GERD, SAN, Management

SAN FRANCISCO, April 25, 2024 /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, today announced the addition of five seasoned leaders to the latest iteration of the company's Product Advisory Board (PAB). The group includes both senior-level medical affairs participation and physician representation.

Key Points: 
  • SAN FRANCISCO, April 25, 2024 /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, today announced the addition of five seasoned leaders to the latest iteration of the company's Product Advisory Board (PAB).
  • The Alucio PAB provides guidance to the company on product strategy, validates product ideas and offers recommendations for feature roadmaps.
  • "Along with input from our customers, this additional guidance is invaluable in our continued product evolution.
  • We also sincerely thank our previous PAB members for their critical insights and contributions to our product success."

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
Martedì, Marzo 26, 2024
Connected, HIV-1, Amazon Prime Video, Breast milk, Face, Hypoesthesia, Patient, Chronic pain, Clostridioides, Heartburn, Lymph, Magnesium, Diarrhea, Myalgia, Spine, Allergy, Muscle weakness, Vonoprazan, Stomach, Vitamin, Dizziness, Potassium, Hip, Risk, Tongue, Chills, DTC, Safety, Food, PPI, Rash, Food and Drug Administration, GERD, Enzyme inhibitor, Skin, Esophagitis, HIV, Rilpivirine, Kidney, FDA, Esophagus, B-12, Weakness, Infection, Indigestion, Smart TV, Seizure, Inflammation, Polyp, Calcium, Extrapyramidal system, Bone fracture, Nausea, Spasm, Urine, Fever, Clostridioides difficile, Bleeding, Blood, Wrist, Blister, Vitamin B12, Human, Medicine, Pharmaceutical industry

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

Gastrointestinal Therapeutics and Diagnostics Technologies and Global Markets Report 2024-2028: Growing Trend toward Screening and Preventive Care and Adoption and Approval of Biological Drugs - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Aprile 5, 2024
Biotechnology, Pharmaceutical, Health, Medical Devices, Sanofi, Growth, Prevalence, AbbVie, Environment, Laxative, Incidence, Antacid, ESG, Gastroesophageal reflux disease, Malignancy, Constipation, Diarrhea, GI, GERD, Irritable bowel syndrome, Prescription, Inflammatory Bowel Diseases, Gastrointestinal disease, OTC, Therapy, Pancreatitis, IBS, Endoscopy, USD, PPI

The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The Global Gastrointestinal Therapeutics and Diagnostics Market was valued at USD 86 Billion in 2023, and is expected to reach USD 122.5 Billion by 2028, rising at a CAGR of 7.30%.
  • This research study analyzes the GI diagnostics and therapeutics market, offers revenue forecasts, assesses future trends and provides strategic recommendations for the success of market participants.
  • This report estimates market data for 2022 (the base year) and forecasts for 2023 through 2028.